Abstract:Background: Tumor-associated macrophages (TAMs) are one of the most abundant immune cells in the pancreatic cancer stroma and are related to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC) patients. Therefore, targeting tumor-associated macrophages is a possible strategy for the treatment of pancreatic cancer.Purpose: We would like to investigate the role of sphingomyelin synthase 2 (SMS2) and the effect of the synthase 2 selective inhibitor YE2 in TAMs and the pancreatic tumor microenvironment. In addition, we also would like to investigate the mechanism by which YE2 attenuates macrophage M2 polarization.Methods: YE2 was utilized to treat macrophages (in vitro) and mice (in vivo). Western blotting and real-time PCR were used to detect the protein levels and mRNA levels of macrophage M2 polarization markers and their downstream signaling pathways. Sphingomyelin synthase 2 gene knockout (KO) mice and their controls were used to establish a PANC-02 orthotopic pancreatic cancer model, and immune cell infiltration in the tumor tissue was analyzed by immunohistochemistry (IHC).Results: We found that sphingomyelin synthase 2 mRNA expression is positively correlated with tumor-associated macrophages, the immunosuppressive microenvironment, and poor prognosis in pancreatic ductal adenocarcinoma patients. Sphingomyelin synthase 2 deficiency was confirmed to have an inhibitory effect on the growth of orthotopic PANC-02 tumors in vivo. The deficiency not only reduced the infiltration of tumor-associated macrophages but also regulated other immune components in the tumor microenvironment. In tissue culture, YE2 inhibited M2 polarization in both bone marrow-derived macrophages (BMDMs) and THP-1 macrophages and eliminated the protumor effect of M2 macrophages. In the mouse model, YE2 treatment reduced the infiltration of TAMs and regulated other immune components in the tumor microenvironment, slowing the progression of PANC-02 tumors. In terms of mechanism, we found that the inhibition of sphingomyelin synthase 2 could downregulate the expression of IL4Rα and CSF1R, thereby attenuating M2 polarization.Conclusion: The sphingomyelin synthase 2 inhibitor YE2 or sphingomyelin synthase 2 deficiency can prevent macrophage M2 polarization in pancreatic cancer, and sphingomyelin synthase 2 could be a new potential target for the treatment of pancreatic cancer.

Sphingomyelin Synthase 2 Deficiency Attenuates Nf Kappa B Activation

Macrophage Sphingomyelin Synthase 2 Deficiency Decreases Atherosclerosis in Mice

Sphingomyelin Synthase 2 Deficiency Decreases Atherosclerosis and Inhibits Inflammation in Mice

Sphingomyelin Synthase 2 is One of the Determinants for Plasma and Liver Sphingomyelin Levels in Mice

Impact of Sphingomyelin Synthase 1 Deficiency on Sphingolipid Metabolism and Atherosclerosis in Mice

Abstract 410: Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism

Inhibition of Sphingomyelin Synthase (SMS) Affects Intracellular Sphingomyelin Accumulation and Plasma Membrane Lipid Organization.

Alterations to Sphingomyelin Metabolism Affect Hemostasis and Thrombosis

Inhibition of Sphingomyelin Synthase 2 Relieves Hypoxia-Induced Cardiomyocyte Injury by Reinforcing Nrf2/ARE Activation Via Modulation of GSK-3β.

The Role of Sphingomyelin Synthase 2 (SMS2) in Platelet Activation and Its Clinical Significance

Sphingosine-1-phosphate Receptor-2 Mediated NFκB Activation Contributes to Tumor Necrosis Factor-Α Induced VCAM-1 and ICAM-1 Expression in Endothelial Cells

Effect of Total SMS Activity on LDL Catabolism in Mice.

Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis.

Sm22 Alpha Suppresses Cytokine- Induced Inflammation And The Transcription Of Nf-Kappa B Inducing Kinase (Nik) By Modulating Srf Transcriptional Activity In Vascular Smooth Muscle Cells

Pharmacologic Inhibition of Sphingomyelin Synthase (SMS) Activity Reduces Apolipoprotein-B Secretion from Hepatocytes and Attenuates Endotoxin-Mediated Macrophage Inflammation.

SM22α suppresses cytokine-induced inflammation and the transcription of NF-κB inducing kinase (Nik) by modulating SRF transcriptional activity in vascular smooth muscle cells.

Sphingomyelin synthase 2 is a positive regulator of the CSF1R-STAT3 pathway in pancreatic cancer-associated macrophage

Sm22 Alpha Inhibits Vascular Inflammation Via Stabilization Of I Kappa B Alpha In Vascular Smooth Muscle Cells

Sphingosine Kinase 2 (sphk2) Depletion Alters Redox Metabolism and Enhances Inflammation in a Diet-Induced MASH Mouse Model

Effect of Liver Total Sphingomyelin Synthase Deficiency on Plasma Lipid Metabolism.

Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll‐Like Receptor 4 to Lipid Rafts